Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
YES
DIRECT
Adoptively transferred tumor-draining lymph node–derived T cells recognize the shared tumor antigen peptide on HLA class I via native TCRs and directly kill targets via perforin/granzyme release and Fas–FasL apoptosis, with supportive cytokine effects (e.g., IFN-γ, TNF).
Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
YES
DIRECT
Adoptively transferred tumor-primed T cells recognize the neoantigen–HLA class II complex via their native TCR and directly kill target cells through perforin/granzyme release and Fas–FasL–mediated apoptosis, with cytokines (e.g., IFN-γ, TNF) augmenting cytotoxicity.
Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
YES
DIRECT
Infused tumor-primed LNL T cells recognize the tumor-associated peptide presented on HLA class II via their native TCRs and directly lyse target cells through perforin/granzyme and/or Fas–FasL pathways, with cytokines (e.g., IFN-γ, TNF) aiding cytotoxicity.
Investigational allogeneic CD19-directed CAR NK cell therapy (adoptive cell immunotherapy) engineered to recognize CD19 and trigger NK cell cytotoxicity to deplete CD19+ B cells.
Off‑the‑shelf allogeneic natural killer cells engineered with a CD19‑specific chimeric antigen receptor containing OX40 and CD3ζ signaling domains and membrane‑bound IL‑15 to enhance survival/persistence. Upon binding CD19 on B cells, the CAR NK cells degranulate (perforin/granzyme) and secrete pro‑inflammatory cytokines, leading to targeted lysis and depletion of CD19+ B cells.
YES
DIRECT
CD19-directed CAR NK cells bind CD19+ cells and kill via NK cell degranulation (perforin/granzyme) leading to lytic/apoptotic death.
An intravenous antibody–drug conjugate consisting of a humanized anti‑TROP2 monoclonal antibody linked to a topoisomerase I–inhibiting cytotoxic payload that is delivered to TROP2‑expressing tumor cells, inducing DNA damage and cell death; indicated for metastatic triple‑negative breast cancer.
Humanized anti‑TROP2 (TACSTD2) monoclonal antibody conjugated to SN‑38 binds TROP2‑expressing tumor cells, is internalized, and releases SN‑38 to inhibit topoisomerase I, stabilizing Topo I–DNA complexes and causing DNA damage, replication arrest, and apoptosis.
YES
DIRECT
Anti‑TROP2 ADC binds TROP2, is internalized, and releases SN‑38, a topoisomerase I inhibitor, causing DNA damage/replication arrest and apoptosis of the target cell.